NERV
Minerva Neurosciences, Inc.4.1700
+0.1300+3.22%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
29.16MP/E (TTM)
-Basic EPS (TTM)
-1.85Dividend Yield
0%Recent Filings
8-K
Roluperidone Phase 3 funded
Minerva Neurosciences raised $80M in October 2025 via private placement to fund its confirmatory Phase 3 roluperidone trial for schizophrenia negative symptoms, set to start Q2 2026 with topline data in 2H 2027. Cash jumped to $82.4M from $21.5M, yet GAAP net loss hit $293.4M for 2025 due to $321.5M non-cash financing charges. Warrants hold key to more cash.
10-K
FY2025 results
Minerva Neurosciences posted a $293.4 million net loss for FY2025 ended December 31, 2025, swinging from $1.4 million net income in 2024, driven by clinical development costs that ballooned its accumulated deficit to $688.8 million from $395.4 million. No revenue generated; pre-revenue biotech burns cash on roluperidone's Phase 3 C19 trial, set to launch Q2 2026 with topline data H2 2027. Q4 details absent. Cash position undisclosed. No guidance given. Clinical trial delays threaten momentum.
8-K
Roluperidone Phase 3 details
Minerva Neurosciences hosts a KOL event today detailing its confirmatory Phase 3 trial for roluperidone targeting schizophrenia's negative symptoms. The trial enrolls 380 patients randomized 1:1 to 64 mg daily or placebo, with PANSS NSFS as primary endpoint at 12 weeks, followed by 40-week relapse phase. Topline efficacy eyed for H2 2027. Trial hinges on FDA feedback.
8-K
Share pool expanded 12.5M
Minerva Neurosciences stockholders approved two key proposals at the December 22, 2025 annual meeting: doubling authorized common shares to 250 million and adding 12.5 million shares to the 2013 Equity Incentive Plan. Fouzia Laghrissi-Thode and Inderjit Kaul joined the board until 2028. Stockholders approved Series A Preferred conversion and executive pay. Boosts equity firepower.
8-K
Appoints Kaul to board, consulting
Minerva Neurosciences appointed Inderjit Kaul, M.D., MPH, to its board on November 14, 2025, expanding to six directors per a prior securities purchase agreement with Vivo Capital investors. Kaul signed a six-month consulting deal at $450/hour for 25-30 hours monthly aiding clinical trial workstreams, including roluperidone's Phase 3, plus a conditional option for 0.7% equity tied to trial milestones. Board adds schizophrenia expertise. His initial director option: 9,500 shares.
IPO
Employees
Sector
Industry
ACAD
ACADIA Pharmaceuticals Inc.
26.80-0.46
BIVI
BioVie Inc.
1.43+0.00
CRVO
CervoMed Inc.
8.35+0.00
LBRX
LB Pharmaceuticals Inc
19.82-0.04
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NGNE
Neurogene Inc.
19.53-0.73
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01